On November 17, 2025, Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), announced the completion of its oversubscribed Series A-2 financing at a substantial valuation step-up over the prior round, with participation from Bambusa's existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners L.P., Salvia GmbH, Janus Henderson Investors, Invus, ADAR1 Capital Management, and Dawn Biopharma (an investment platform controlled by KKR). Wilson Sonsini Goodrich & Rosati advised Bambusa on the transaction.

Proceeds from the funding will accelerate the development of their BBT003 and BBT004 programs, broaden Bambusa's bispecific antibody platform into new I&I indications, and strengthen core development infrastructure to support rapid progression through upcoming clinical and regulatory milestones.

The team that advised Bambusa includes Jennifer Fang and Erin Wolter.

For more information, please see Bambusa’s press release.